In February, the FDA determined that the shortage of Wegovy and Ozempic had been resolved. Compounding pharmacy groups have already filed a lawsuit in an attempt to overturn the agency's determination. If their efforts fail, as seems likely, semaglutide sales growth in 2025 could outpace 2024.